TÜBİTAK-2209A-(1919B011701745) ve CÜBAP (ECZ018)
The discovery of many drugs in recent years provides a definitive solution in the treatment of various diseases, but today, despite the discovery of many effective anticancer drugs, there are various types of cancer that have limitations in treatment and are still not completely curable. Since most of these limitations are due to cancer cells gaining resistance or compounds only being effective in certain types of cancer cells, the search for more effective anticancer drugs that are also effective in these types of cancer is inevitable. Cabozantinib is in medical use as a highly effective anticancer drug in various types of cancer, such as medullary thyroid cancer and kidney cancer. The anticancer properties of the Cabozantinib compound have attracted more attention in recent years, however, more studies are needed to define the anticancer activities of this compound. In our study, the interactions of Cabozantinib with topoisomerase enzymes, were demonstrated through in vitro enzyme activity tests, and the anti-proliferative effect of Cabozantinib was studied on MCF7, A549 and PC3 cell lines. By analyzing the interactions of the Cabozantinib with topoisomerases, the action mechanisms of the compound at the molecular level was evaluated.
Topoisomerase enzymes Cancer CabozanJnib Tyrosine kinase inhibitor DNA damage.
TÜBİTAK-2209A ve CÜBAP
TÜBİTAK-2209A-(1919B011701745) ve CÜBAP (ECZ018)
Birincil Dil | İngilizce |
---|---|
Konular | Enzimler, Temel Farmakoloji, Eczacılık ve İlaç Bilimleri (Diğer) |
Bölüm | Natural Sciences |
Yazarlar | |
Proje Numarası | TÜBİTAK-2209A-(1919B011701745) ve CÜBAP (ECZ018) |
Yayımlanma Tarihi | 28 Aralık 2023 |
Gönderilme Tarihi | 16 Ekim 2023 |
Kabul Tarihi | 15 Aralık 2023 |
Yayımlandığı Sayı | Yıl 2023 |